-
Janet
Brown,
R.
Cook,
P.
Major,
A.
Lipton,
F.
Saad,
Matthew
Smith,
Ker-Ai
Lee,
M.
Zheng,
Y.
Hei,
R.
Coleman
(2005)
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Journal of the National Cancer Institute, 97 1
-
(2011)
GTx provides corporate update and reports first quarter 2011 financial results
-
SL
Greenspan,
JB
Nelson,
DL
Trump
(2007)
Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial
Ann Intern Med, 146
-
A.
Brufsky
(2008)
Zoledronic acid for cancer therapy-induced and postmenopausal bone loss
Expert Opinion on Pharmacotherapy, 9
-
L.
Costa,
L.
Demers,
A.
Gouveia‐Oliveira,
J.
Schaller,
E.
Costa,
M.
Moura,
A.
Lipton
(2002)
Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 3
-
K.
Markou,
A.
Nikolaou,
C.
Themelis
(2011)
National Comprehensive Cancer Network (NCCN) Head and Neck Cancers NCCN Clinical Practice Guidelines in Oncology . 2010.
-
A.
Brewster,
G.
Hortobagyi,
K.
Broglio,
S.
Kau,
C.
Santa-Maria,
B.
Arun,
A.
Buzdar,
D.
Booser,
V.
Valero,
M.
Bondy,
F.
Esteva
(2008)
Residual risk of breast cancer recurrence 5 years after adjuvant therapy.
Journal of the National Cancer Institute, 100 16
-
Matthew
Smith,
M.
Fallon,
Hang
Lee,
J.
Finkelstein
(2004)
Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial.
The Journal of clinical endocrinology and metabolism, 89 8
-
J.
Mohler,
R.
Bahnson,
B.
Boston,
J.
Busby,
A.
D'Amico,
J.
Eastham,
C.
Enke,
D.
George,
E.
Horwitz,
R.
Huben,
P.
Kantoff,
M.
Kawachi,
M.
Kuettel,
P.
Lange,
G.
Macvicar,
E.
Plimack,
J.
Pow-Sang,
M.
Roach,
E.
Rohren,
B.
Roth,
D.
Shrieve,
Matthew
Smith,
S.
Srinivas,
P.
Twardowski,
P.
Walsh
(2010)
NCCN clinical practice guidelines in oncology: prostate cancer.
Journal of the National Comprehensive Cancer Network : JNCCN, 8 2
-
M.
Smith,
F.
Mcgovern,
A.
Zietman,
M.
Fallon,
D.
Hayden,
D.
Schoenfeld,
P.
Kantoff,
J.
Finkelstein
(2001)
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
The New England journal of medicine, 345 13
-
M.
Tabrizi,
Chih-Ming
Tseng,
L.
Roskos
(2006)
Elimination mechanisms of therapeutic monoclonal antibodies.
Drug discovery today, 11 1-2
-
F
Cardoso,
L
Fallowfield,
A
Costa
(2011)
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ann Oncol, 22
-
A.
Stopeck,
A.
Lipton,
J.
Body,
G.
Steger,
K.
Tonkin,
R.
Boer,
M.
Lichinitser,
Y.
Fujiwara,
D.
Yardley,
M.
Viniegra,
M.
Fan,
Q.
Jiang,
R.
Dansey,
S.
Jun,
A.
Braun
(2010)
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 35
-
GD
Roodman
(2004)
Mechanisms of bone metastasis
N Engl J Med, 350
-
B.
Hillner,
J.
Ingle,
R.
Chlebowski,
J.
Gralow,
G.
Yee,
N.
Janjan,
J.
Cauley,
B.
Blumenstein,
K.
Albain,
A.
Lipton,
Susan
Brown
(2003)
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 21
-
G.
Ellis,
H.
Bone,
R.
Chlebowski,
D.
Paul,
S.
Spadafora,
M.
Fan,
Dennis
Kim
(2009)
Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study
Breast Cancer Research and Treatment, 118
-
N.
Mottet,
J.
Bellmunt,
M.
Bolla,
S.
Joniau,
M.
Mason,
V.
Matveev,
Hans-Peter
Schmid,
T.
Kwast,
T.
Wiegel,
F.
Zattoni,
Axel
Heidenreich
(2011)
[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Actas urologicas espanolas, 35 10
-
Matthew
Smith,
B.
Egerdie,
Narciso
Toriz,
R.
Feldman,
T.
Tammela,
F.
Saad,
J.
Heracek,
M.
Szwedowski,
C.
Ke,
Amy
Kupic,
B.
Leder,
C.
Goessl
(2009)
Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
The New England journal of medicine, 361 8
-
Matthew
Smith,
J.
Finkelstein,
F.
Mcgovern,
A.
Zietman,
M.
Fallon,
D.
Schoenfeld,
P.
Kantoff
(2002)
Changes in body composition during androgen deprivation therapy for prostate cancer.
The Journal of clinical endocrinology and metabolism, 87 2
-
B.
Clarke
(2008)
Effect of Once-Weekly Oral Alendronate on Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: A Randomized Trial
Yearbook of Endocrinology, 2008
-
Charles
Shapiro,
Susan
Halabi,
V.
Hárs,
L.
Archer,
D.
Weckstein,
Jeffrey
Kirshner,
William
Sikov,
Eric
Winer,
H.
Burstein,
Clifford
Hudis,
Claudine
Isaacs,
R.
Schilsky,
E.
Paskett
(2011)
Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.
European journal of cancer, 47 5
-
N
Sharifi,
JL
Gulley,
WL
Dahut
(2005)
Androgen deprivation therapy for prostate cancer
JAMA, 294
-
A.
Brufsky,
W.
Harker,
J.
Beck,
R.
Carroll,
E.
Tan-chiu,
C.
Seidler,
J.
Hohneker,
L.
Lacerna,
S.
Petrone,
E.
Perez
(2007)
Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 7
-
J.
Gralow,
J.
Biermann,
A.
Farooki,
M.
Fornier,
R.
Gagel,
Rashmi
Kumar,
Georgia
Litsas,
R.
McKay,
D.
Podoloff,
S.
Srinivas,
C.
Poznak
(2006)
NCCN Task Force Report: Bone Health in Cancer Care.
Journal of the National Comprehensive Cancer Network : JNCCN, 7 Suppl 3
-
R.
Coleman
(2005)
Supportive care in oncology
Supportive Care in Cancer, 13
-
A.
Brufsky,
L.
Bosserman,
R.
Caradonna,
B.
Haley,
C.
Jones,
H.
Moore,
Lixian
Jin,
G.
Warsi,
S.
Ericson,
E.
Perez
(2009)
Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
Clinical breast cancer, 9 2
-
D.
Hershman,
D.
McMahon,
K.
Crew,
T.
Shao,
S.
Cremers,
L.
Brafman,
D.
Awad,
E.
Shane
(2010)
Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment.
The Journal of clinical endocrinology and metabolism, 95 2
-
C.
Ryan,
D.
Huo,
L.
Demers,
T.
Beer,
L.
Lacerna
(2006)
Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.
The Journal of urology, 176 3
-
H.
Burstein,
J.
Griggs,
A.
Prestrud,
S.
Temin
(2010)
American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.
Journal of oncology practice, 6 5
-
(2003)
Prevention and management of osteoporosis: report of a WHO scientific group
-
C.
Poznak,
R.
Hannon,
J.
Mackey,
M.
Campone,
J.
Apffelstaedt,
G.
Clack,
D.
Barlow,
A.
Makris,
R.
Eastell
(2010)
Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 6
-
S.
Hines,
B.
Mincey,
J.
Sloan,
Sachdev
Thomas,
E.
Chottiner,
C.
Loprinzi,
M.
Carlson,
P.
Atherton,
M.
Salim,
E.
Perez
(2009)
Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 7
-
D.
Bliuc,
N.
Nguyen,
V.
Milch,
Tuan
Nguyen,
J.
Eisman,
J.
Center
(2009)
Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women.
JAMA, 301 5
-
H.
Eidtmann,
R.
Boer,
N.
Bundred,
A.
Llombart-Cussac,
N.
Davidson,
P.
Neven,
G.
Minckwitz,
J.
Miller,
N.
Schenk,
R.
Coleman
(2010)
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.
Annals of oncology : official journal of the European Society for Medical Oncology, 21 11
-
C.
Johnston,
C.
Slemenda
(1992)
Diagnosis of Osteoporosis
Southern Medical Journal, 85
-
C.
Brugmann
(2010)
Prevention and treatment of side-effects of systemic treatment: bone loss
-
Description
(2003)
FOSAMAX ® ( ALENDRONATE SODIUM ) TABLETS AND ORAL SOLUTION
-
(1994)
World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: technical report 843: World Health Organization
-
A.
Kearns,
D.
Northfelt,
A.
Dueck,
P.
Atherton,
S.
Dakhil,
K.
Rowland,
J.
Fuloria,
P.
Flynn,
T.
Dentchev,
C.
Loprinzi
(2010)
Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8
Supportive Care in Cancer, 18
-
F.
Bertoldo,
G.
Tonini,
B.
Vincenzi,
D.
Santini
(2009)
Medical oncology: Zoledronic acid prevents bone loss in early-stage breast cancer
Nature Reviews Clinical Oncology, 6
-
N.
Bundred,
I.
Campbell,
N.
Davidson,
R.
DeBoer,
H.
Eidtmann,
A.
Monnier,
P.
Neven,
G.
Minckwitz,
Joel
Miller,
N.
Schenk,
R.
Coleman
(2008)
Effective inhibition of aromatase inhibitor‐associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole
Cancer, 112
-
(2007)
J Clin Oncol
-
D.
Hershman,
D.
McMahon,
K.
Crew,
S.
Cremers,
D.
Irani,
G.
Cucchiara,
L.
Brafman,
E.
Shane
(2008)
Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 29
-
JA
Kanis,
LJ
Melton,
C
Christiansen
(1994)
The diagnosis of osteoporosis
J Bone Miner Res, 9
-
Jean
Kaufman,
E.
Orwoll,
S.
Goemaere,
J.
Martin,
A.
Hossain,
G.
Dalsky,
R.
Lindsay,
B.
Mitlak
(2005)
Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy
Osteoporosis International, 16
-
E.
Wibowo,
P.
Schellhammer,
R.
Wassersug
(2011)
Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy.
The Journal of urology, 185 1
-
L.
Vandenput,
C.
Ohlsson
(2009)
Estrogens as regulators of bone health in men
Nature Reviews Endocrinology, 5
-
J.
Pfeilschifter,
I.
Diel
(2000)
Osteoporosis due to cancer treatment: pathogenesis and management.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 7
-
J.
Beebe-Dimmer,
K.
Cetin,
V.
Shahinian,
H.
Morgenstern,
C.
Yee,
K.
Schwartz,
J.
Acquavella
(2012)
Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States
Pharmacoepidemiology and Drug Safety, 21
-
J.
Lester,
D.
Dodwell,
O.
Purohit,
S.
Gutcher,
S.
Ellis,
R.
Thorpe,
J.
Horsman,
Janet
Brown,
R.
Hannon,
R.
Coleman
(2008)
Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer
Clinical Cancer Research, 14
-
A.
Heidenreich,
J.
Bellmunt,
M.
Bolla,
S.
Joniau,
M.
Mason,
V.
Matveev,
N.
Mottet,
H.
Schmid,
T.
Kwast,
T.
Wiegel,
F.
Zattoni
(2011)
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.
European urology, 59 1
-
D.
Pfister,
K.
Ang,
D.
Brizel
(2012)
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
-
S.
Khosla
(2010)
Update on estrogens and the skeleton.
The Journal of clinical endocrinology and metabolism, 95 8
-
A.
Lipton,
R.
Uzzo,
R.
Amato,
G.
Ellis,
B.
Hakimian,
G.
Roodman,
Matthew
Smith
(2009)
The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors.
Journal of the National Comprehensive Cancer Network : JNCCN, 7 Suppl 7
-
M.
Garassino,
D.
Schrijvers,
B.
Zakotnik
(2010)
Highlights of the Joint ECCO 15-34th ESMO Multidisciplinary Congress
, 4
-
K.
Fizazi,
M.
Carducci,
Matthew
Smith,
R.
Damião,
Janet
Brown,
L.
Karsh,
P.
Milecki,
N.
Shore,
M.
Rader,
Huei
Wang,
Q.
Jiang,
Sylvia
Tadros,
R.
Dansey,
C.
Goessl
(2011)
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
The Lancet, 377
-
S.
Campbell,
N.
Bhoopalam,
Thomas
Moritz,
M.
Pandya,
P.
Iyer,
P.
Vanveldhuizen,
N.
Ellis,
Lizy
Thottapurathu,
H.
Garewal,
S.
Warren,
N.
Friedman,
D.
Reda
(2010)
The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis.
Urology, 75 5
-
S.
Greenspan,
J.
Nelson,
D.
Trump,
J.
Wagner,
Megan
Miller,
S.
Perera,
N.
Resnick
(2008)
Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 27
-
MR
Smith,
J
Eastham,
DM
Gleason
(2003)
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer
J Urol, 169
-
R.
Moos
(2005)
Bisphosphonate treatment recommendations for oncologists.
The oncologist, 10 Suppl 1
-
S.
Hines,
B.
Mincey,
T.
Dentchev,
J.
Sloan,
E.
Perez,
David
Johnson,
P.
Schaefer,
S.
Alberts,
Heshan
Liu,
S.
Kahanic,
M.
Mazurczak,
D.
Nikcevich,
C.
Loprinzi
(2009)
Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC
Breast Cancer Research and Treatment, 117
-
R.
Casey,
Z.
Gesztesi,
J.
Rochford
(2010)
Long term zoledronic acid during androgen blockade for prostate cancer.
The Canadian journal of urology, 17 3
-
L.
Holmberg,
Harald
Anderson
(2004)
HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomised comparison: trial stopped
The Lancet, 363
-
Connie
Limburg
(2007)
Screening, prevention, detection, and treatment of cancer therapy-induced bone loss in patients with breast cancer.
Oncology nursing forum, 34 1
-
J.
Kanis,
O.
Johnell,
A.
Odén,
A.
Dawson,
C.
Laet,
B.
Jönsson
(2001)
Ten Year Probabilities of Osteoporotic Fractures According to BMD and Diagnostic Thresholds
Osteoporosis International, 12
-
R.
Israeli,
S.
Rosenberg,
D.
Saltzstein,
J.
Gottesman,
Howard
Goldstein,
G.
Hull,
D.
Tran,
G.
Warsi,
L.
Lacerna
(2007)
The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
Clinical genitourinary cancer, 5 4
-
S
Aebi,
T
Davidson,
G
Gruber
(2011)
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ann Oncol, 22
-
F.
Cardoso,
E.
Senkus-Konefka,
L.
Fallowfield,
A.
Costa,
M.
Castiglione
(2010)
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology, 21 Suppl 5
-
Matthew
Smith,
Ronald
Morton,
K.
Barnette,
Paul
Sieber,
S.
Malkowicz,
D.
Rodriguez,
Michael
Hancock,
Mitchell
Steiner
(2010)
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.
The Journal of urology, 184 4
-
A.
Brufsky
(2006)
Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Seminars in oncology, 33 2 Suppl 7
-
Matthew
Smith,
B.
Egerdie,
P.
Sieber,
T.
Tammela,
F.
Saad,
C.
Ke,
B.
Leder,
R.
Dansey,
C.
Goessl
(2009)
7005 Overall survival in men with and without prevalent vertebral fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
Ejc Supplements, 7
-
B.
Riggs,
S.
Khosla,
L.
Melton
(2002)
Sex steroids and the construction and conservation of the adult skeleton.
Endocrine reviews, 23 3
-
J.
Center,
Tuan
Nguyen,
D.
Schneider,
P.
Sambrook,
J.
Eisman
(1999)
Mortality after all major types of osteoporotic fracture in men and women: an observational study
The Lancet, 353
-
J.
Kanis,
E.
McCloskey,
T.
Powles,
A.
Paterson,
S.
Ashley,
T.
Spector
(1999)
A high incidence of vertebral fracture in women with breast cancer
British Journal of Cancer, 79
-
G.
Ellis,
H.
Bone,
R.
Chlebowski,
D.
Paul,
S.
Spadafora,
Judy
Smith,
M.
Fan,
S.
Jun
(2008)
Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 30
-
N.
Bhoopalam,
S.
Campbell,
Thomas
Moritz,
W.
Broderick,
P.
Iyer,
A.
Arcenas,
P.
Veldhuizen,
N.
Friedman,
D.
Reda,
S.
Warren,
H.
Garewal
(2009)
Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
The Journal of urology, 182 5
-
K.
Bylow,
S.
Mohile,
W.
Stadler,
W.
Dale
(2007)
Does androgen‐deprivation therapy accelerate the development of frailty in older men with prostate cancer?
Cancer, 110
-
Matthew
Smith,
S.
Malkowicz,
Franklin
Chu,
J.
Forrest,
D.
Price,
P.
Sieber,
K.
Barnette,
D.
Rodriguez,
Mitchell
Steiner
(2008)
Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study.
The Journal of urology, 179 1
-
J.
Bono,
C.
Logothetis,
A.
Molina,
K.
Fizazi,
S.
North,
L.
Chu,
K.
Chi,
Robert
Jones,
O.
Goodman,
F.
Saad,
J.
Staffurth,
P.
Mainwaring,
S.
Harland,
T.
Flaig,
Thomas
Hutson,
T.
Cheng,
H.
Patterson,
J.
Hainsworth,
C.
Ryan,
C.
Sternberg,
S.
Ellard,
A.
Flechon,
M.
Saleh,
M.
Scholz,
E.
Efstathiou,
A.
Zivi,
D.
Bianchini,
Y.
Loriot,
N.
Chieffo,
T.
Kheoh,
C.
Haqq,
H.
Scher
(2011)
Abiraterone and increased survival in metastatic prostate cancer.
The New England journal of medicine, 364 21
-
R.
Coleman,
P.
Major,
A.
Lipton,
Janet
Brown,
Ker-Ai
Lee,
Matthew
Smith,
F.
Saad,
M.
Zheng,
Y.
Hei,
J.
Seaman,
R.
Cook
(2005)
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 22
-
M.
Aapro
(2004)
Long-term implications of bone loss in breast cancer.
Breast, 13 Suppl 1
-
P.
Bekker,
D.
Holloway,
Amy
Rasmussen,
Robyn
Murphy,
Steven
Martin,
P.
Leese,
Gregory
Holmes,
C.
Dunstan,
A.
DePaoli
(2004)
A Single‐Dose Placebo‐Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women
Journal of Bone and Mineral Research, 19
-
J.
Forbes,
J.
Cuzick,
A.
Buzdar,
A.
Howell,
J.
Tobias,
M.
Baum
(2008)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
The Lancet. Oncology, 9 1
-
R.
Neer,
C.
Arnaud,
J.
Zanchetta,
R.
Prince,
G.
Gaich,
J.
Reginster,
A.
Hodsman,
E.
Eriksen,
S.
Ish-shalom,
H.
Genant,
O.
Wang,
B.
Mitlak
(2001)
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
The New England journal of medicine, 344 19
-
L.
Michaud,
S.
Goodin
(2006)
Cancer-treatment-induced bone loss, part 2.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 63 6
-
J.
Finkelstein,
Sarah
Brockwell,
Vinay
Mehta,
G.
Greendale,
M.
Sowers,
B.
Ettinger,
J.
Lo,
J.
Johnston,
J.
Cauley,
M.
Danielson,
R.
Neer
(2008)
Bone mineral density changes during the menopause transition in a multiethnic cohort of women.
The Journal of clinical endocrinology and metabolism, 93 3
-
H.
Ahlborg,
O.
Johnell,
C.
Turner,
G.
Rannevik,
M.
Karlsson
(2003)
Bone loss and bone size after menopause.
The New England journal of medicine, 349 4
-
A.
Buzdar,
A.
Howell,
J.
Cuzick,
C.
Wale,
W.
Distler,
G.
Hoctin-Boes,
J.
Houghton,
G.
Locker,
Nabholtz
Jm
(2006)
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
The Lancet. Oncology, 7 8
-
Matthew
Smith,
Melissa
Goode,
A.
Zietman,
F.
Mcgovern,
Hang
Lee,
J.
Finkelstein
(2004)
Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 13
-
Matthew
Smith,
F.
Saad,
R.
Coleman,
N.
Shore,
K.
Fizazi,
B.
Tombal,
K.
Miller,
P.
Sieber,
L.
Karsh,
R.
Damião,
T.
Tammela,
B.
Egerdie,
H.
Poppel,
J.
Chin,
J.
Morote,
F.
Gómez‐Veiga,
T.
Borkowski,
Z.
Ye,
Amy
Kupic,
R.
Dansey,
C.
Goessl
(2012)
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
The Lancet, 379
-
(2011)
Novartis Pharmaceuticals Corporation Miacalcin (calcitonen salmon) (injection or nasal spray) full prescribing information
-
L.
Sutjandra,
Rachelle
Rodriguez,
S.
Doshi,
M.
Ma,
M.
Peterson,
G.
Jang,
A.
Chow,
J.
Pérez-Ruixo
(2011)
Population Pharmacokinetic Meta-Analysis of Denosumab in Healthy Subjects and Postmenopausal Women with Osteopenia or Osteoporosis
Clinical Pharmacokinetics, 50
-
K.
Ishizaka,
T.
Machida,
Shuichiro
Kobayashi,
N.
Kanbe,
S.
Kitahara,
Ken‐ichiro
Yoshida
(2007)
Preventive effect of risedronate on bone loss in men receiving androgen‐deprivation therapy for prostate cancer
International Journal of Urology, 14
-
R.
Wolters,
A.
Regierer,
A.
Regierer,
L.
Schwentner,
V.
Geyer,
K.
Possinger,
R.
Kreienberg,
M.
Wischnewsky,
A.
Wöckel
(2012)
A comparison of international breast cancer guidelines - do the national guidelines differ in treatment recommendations?
European journal of cancer, 48 1
-
H
Kodama,
M
Nose,
S
Niida
(1991)
Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells
J Exp Med, 173
-
W.
Dougall,
M.
Glaccum,
K.
Charrier,
Kathy
Rohrbach,
K.
Brasel,
T.
Smedt,
E.
Daro,
Jeffery
Smith,
Mark
Tometsko,
C.
Maliszewski,
A.
Armstrong,
Victor
Shen,
S.
Bain,
D.
Cosman,
Dirk
Anderson,
P.
Morrissey,
J.
Peschon,
J.
Schuh
(1999)
RANK is essential for osteoclast and lymph node development.
Genes & development, 13 18
-
K.
Roehl,
Misop
Han,
C.
Ramos,
J.
Antenor,
W.
Catalona
(2004)
Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results.
The Journal of urology, 172 3
-
(2010)
GLOBOCAN Cancer Fact Sheets 2008: Breast Cancer
GLOBOCAN 2008
-
G.
Aus,
C.
Abbou,
M.
Bolla,
A.
Heidenreich,
H.
Schmid,
H.
Poppel,
J.
Wolff,
F.
Zattoni
(2001)
EAU guidelines on prostate cancer.
European urology, 48 4
-
S.
Khosla
(2010)
Update in male osteoporosis.
The Journal of clinical endocrinology and metabolism, 95 1
-
(2011)
Novartis Pharmaceuticals Corporation. Reclast (zoledronic acid) injection
-
C.
Schlaich,
Helmut
Minne,
T.
Bruckner,
G.
Wagner,
H.
Gebest,
M.
Grunze,
Reinhard
Ziegler,
G.
Leidig‐Bruckner
(1998)
Reduced Pulmonary Function in Patients with Spinal Osteoporotic Fractures
Osteoporosis International, 8
-
P.
Hadji,
J.
Body,
M.
Aapro,
A.
Brufsky,
R.
Coleman,
T.
Guise,
A.
Lipton,
M.
Tubiana‐Hulin
(2008)
Practical guidance for the management of aromatase inhibitor-associated bone loss.
Annals of oncology : official journal of the European Society for Medical Oncology, 19 8
-
(2003)
World Health Organization. Prevention and management of osteoporosis: report of a WHO scientific group
-
(2007)
Chemoprevention of breast cancer with selective oestrogenreceptor modulators
-
Clinical Medicine Insights: Oncology
-
L.
Gibiansky,
L.
Sutjandra,
S.
Doshi,
J.
Zheng,
W.
Sohn,
M.
Peterson,
G.
Jang,
A.
Chow,
J.
Pérez-Ruixo
(2012)
Population Pharmacokinetic Analysis of Denosumab in Patients with Bone Metastases from Solid Tumours
Clinical Pharmacokinetics, 51
-
H
Fleisch
(1998)
Bisphosphonates: mechanisms of action
Endocr Rev, 19
-
M.
Aapro,
P.
Abrahamsson,
J.
Body,
R.
Coleman,
R.
Colomer,
L.
Costa,
L.
Crinò,
L.
Dirix,
M.
Gnant,
J.
Gralow,
P.
Hadji,
G.
Hortobagyi,
W.
Jonat,
A.
Lipton,
A.
Monnier,
A.
Paterson,
R.
Rizzoli,
F.
Saad,
B.
Thürlimann
(2008)
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel.
Annals of oncology : official journal of the European Society for Medical Oncology, 19 3
-
C.
Markopoulos,
E.
Tzoracoleftherakis,
A.
Polychronis,
B.
Venizelos,
U.
Dafni,
G.
Xepapadakis,
J.
Papadiamantis,
V.
Zobolas,
J.
Misitzis,
K.
Kalogerakos,
A.
Sarantopoulou,
N.
Siasos,
D.
Koukouras,
Z.
Antonopoulou,
Spyros
Lazarou,
H.
Gogas
(2010)
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial
Breast Cancer Research : BCR, 12
-
T.
Polascik,
R.
Given,
C.
Metzger,
Sydney
Julian,
J.
Vestal,
G.
Karlin,
C.
Barkley,
D.
Bilhartz,
L.
McWhorter,
L.
Lacerna
(2005)
Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.
Urology, 66 5
-
HJ
Burstein,
AA
Prestrud,
J
Seidenfeld
(2010)
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer
J Clin Oncol, 28
-
A.
Horwich,
C.
Parker,
C.
Bangma,
V.
Kataja
(2010)
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology, 21 Suppl 5
-
E.
Senkus,
S.
Kyriakides,
F.
Penault-Llorca,
P.
Poortmans,
Alistair
Thompson,
S.
Zackrisson,
F.
Cardoso
(2019)
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology, 24 Suppl 6
-
BriefDefinitive Report Essential Role of Macrophage Colony-Stimulating Factor in the Osteoclast Differentiation Supported by
-
Zhao
Chen,
M.
Maricic,
M.
Pettinger,
C.
Ritenbaugh,
A.
Lopez,
D.
Barad,
M.
Gass,
M.
LeBoff,
T.
Bassford
(2005)
Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer
Cancer, 104
-
International Osteoporosis Foundation. Facts and statistics about osteoporosis and its impact
-
S
Papapoulos,
R
Chapurlat,
C
Libanati
(2011)
Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension
J Bone Miner Res
-
S.
Cummings,
L.
Melton
(2002)
Epidemiology and outcomes of osteoporotic fractures
The Lancet, 359
-
Matthew
Smith,
J.
Eastham,
D.
Gleason,
D.
Shasha,
S.
Tchekmedyian,
N.
Zinner
(2012)
Original Articles RANDOMIZED CONTROLLED TRIAL OF ZOLEDRONIC ACID TO PREVENT BONE LOSS IN MEN RECEIVING ANDROGEN DEPRIVATION THERAPY FOR NONMETASTATIC PROSTATE CANCER
-
M.
Roizen
(2010)
Mortality Risk Associated With Low-Trauma Osteoporotic Fracture and Subsequent Fracture in Men and Women
Yearbook of Anesthesiology and Pain Management, 2010
-
J.
Body
(2011)
Increased fracture rate in women with breast cancer: a review of the hidden risk
BMC Cancer, 11
-
Zhao
Chen,
M.
Maricic,
T.
Bassford,
M.
Pettinger,
C.
Ritenbaugh,
A.
López,
D.
Barad,
M.
Gass,
M.
LeBoff
(2005)
Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study.
Archives of internal medicine, 165 5
-
B.
Clarke
(2012)
Five Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the First Two Years of the FREEDOM Extension
Yearbook of Endocrinology, 2012
-
G.
Rodan,
H
Fleisch
(1996)
Bisphosphonates: mechanisms of action.
The Journal of clinical investigation, 97 12
-
B.
Kiratli,
S.
Srinivas,
I.
Perkash,
M.
Terris
(2001)
Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.
Urology, 57 1
-
Matthew
Smith,
F.
Saad,
B.
Egerdie,
M.
Szwedowski,
T.
Tammela,
C.
Ke,
B.
Leder,
C.
Goessl
(2009)
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.
The Journal of urology, 182 6
-
G.
Roodman
(2004)
Mechanisms of bone metastasis.
Discovery medicine, 4 22
-
N.
Mottet,
J.
Bellmunt,
M.
Bolla,
S.
Joniau,
M.
Mason,
V.
Matveev,
H.
Schmid,
T.
Kwast,
T.
Wiegel,
F.
Zattoni,
A.
Heidenreich
(2011)
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
European urology, 59 4
-
A.
Cheung,
L.
Tile,
S.
Cardew,
S.
Pruthi,
J.
Robbins,
G.
Tomlinson,
M.
Kapral,
S.
Khosla,
S.
Majumdar,
M.
Erlandson,
J.
Scher,
Hanxian
Hu,
Alice
Demaras,
L.
Lickley,
L.
Bordeleau,
C.
Elser,
J.
Ingle,
H.
Richardson,
P.
Goss
(2012)
Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
The Lancet. Oncology, 13 3
-
W.
Anderson,
N.
Chatterjee,
W.
Ershler,
O.
Brawley
(2002)
Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database
Breast Cancer Research and Treatment, 76
-
(2008)
GLOBOCAN Cancer Fact Sheets 2008: Prostate Cancer
-
B.
Abrahamsen,
T.
Staa,
R.
Ariely,
M.
Olson,
Chris
Cooper,
Chris
Cooper
(2009)
Excess mortality following hip fracture: a systematic epidemiological review
Osteoporosis International, 20
-
W.
Boyle,
W.
Simonet,
D.
Lacey
(2003)
Osteoclast differentiation and activation
Nature, 423
-
R.
Theriault,
J.
Biermann,
Elizabeth
Brown,
A.
Brufsky,
L.
Demers,
R.
Grewal,
Theresa
Guise,
R.
Jackson,
K.
McEnery,
D.
Podoloff,
P.
Ravdin,
C.
Shapiro,
Matthew
Smith,
C.
Poznak
(2006)
NCCN Task Force Report: Bone Health and Cancer Care.
Journal of the National Comprehensive Cancer Network : JNCCN, 4 Suppl 2
-
D.
Loblaw,
Katherine
Virgo,
R.
Nam,
M.
Somerfield,
E.
Ben-Josef,
D.
Mendelson,
R.
Middleton,
S.
Sharp,
Thomas
Smith,
J.
Talcott,
M.
Taplin,
N.
Vogelzang,
J.
Wade,
C.
Bennett,
H.
Scher
(2007)
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 12
-
D.
Lacey,
E.
Timms,
H.
Tan,
M.
Kelley,
C.
Dunstan,
Tim
Burgess,
R.
Elliott,
A.
Colombero,
G.
Elliott,
S.
Scully,
H.
Hsu,
J.
Sullivan,
N.
Hawkins,
E.
Davy,
Charles
Capparelli,
A.
Eli,
Y.
Qian,
S.
Kaufman,
I.
Sarosi,
V.
Shalhoub,
G.
Senaldi,
Jane
Guo,
J.
Delaney,
W.
Boyle
(1998)
Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation
Cell, 93
-
Matthew
Smith,
F.
Saad,
B.
Egerdie,
P.
Sieber,
T.
Tammela,
B.
Leder,
C.
Ke,
C.
Goessl
(2011)
Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer
Journal of Bone and Mineral Research, 26
-
Chris
Cooper
(1997)
The crippling consequences of fractures and their impact on quality of life.
The American journal of medicine, 103 2A
-
J.
Kanis,
Didier
Hans,
Chris
Cooper,
Chris
Cooper,
Sanford
Baim,
J.
Bilezikian,
N.
Binkley,
J.
Cauley,
J.
Compston,
B.
Dawson-Hughes,
G.
Fuleihan,
H.
Johansson,
W.
Leslie,
E.
Lewiecki,
M.
Luckey,
A.
Odén,
S.
Papapoulos,
C.
Poiană,
R.
Rizzoli,
D.
Wahl,
E.
McCloskey
(2011)
Interpretation and use of FRAX in clinical practice
Osteoporosis International, 22
-
J.
Mohler,
R.
Babaian,
R.
Bahnson,
B.
Boston,
A.
D'Amico,
J.
Eastham,
R.
Hauke,
R.
Huben,
P.
Kantoff,
M.
Kawachi,
M.
Kuettel,
P.
Lange,
C.
Logothetis,
G.
Macvicar,
A.
Pollack,
J.
Pow-Sang,
M.
Roach,
H.
Sandler,
D.
Shrieve,
S.
Srinivas,
P.
Twardowski,
D.
Urban,
P.
Walsh
(2007)
Prostate cancer. Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN, 5 7
-
J.
Cuzick,
I.
Šestak,
M.
Baum,
A.
Buzdar,
A.
Howell,
M.
Dowsett,
J.
Forbes
(2010)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
The Lancet. Oncology, 11 12
-
Forteo (teriparatide injection) full prescribing information
-
S.
Hines,
J.
Sloan,
P.
Atherton,
E.
Perez,
S.
Dakhil,
David
Johnson,
P.
Reddy,
R.
Dalton,
B.
Mattar,
C.
Loprinzi
(2010)
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.
Breast, 19 2
-
R.
Burge,
B.
Dawson-Hughes,
D.
Solomon,
J.
Wong,
Alison
King,
A.
Tosteson
(2007)
Incidence and Economic Burden of Osteoporosis‐Related Fractures in the United States, 2005–2025
Journal of Bone and Mineral Research, 22
-
J.
Mackey,
A.
Joy
(2005)
Skeletal health in postmenopausal survivors of early breast cancer
International Journal of Cancer, 114
-
A.
Brufsky
(2008)
Bone health issues in women with early-stage breast cancer receiving aromatase inhibitors
Current Oncology Reports, 10
-
M.
Gnant,
B.
Mlineritsch,
G.
Luschin-Ebengreuth,
S.
Grampp,
Helmut
Kaessmann,
M.
Schmid,
C.
Menzel,
J.
Piswanger‐Soelkner,
A.
Galid,
M.
Mittlboeck,
H.
Hausmaninger,
R.
Jakesz
(2007)
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 7
-
T.
Diamond,
C.
Higano,
Matthew
Smith,
T.
Guise,
F.
Singer
(2004)
Osteoporosis in men with prostate carcinoma receiving androgen‐deprivation therapy
Cancer, 100
-
A.
Brufsky
(2008)
Cancer treatment-induced bone loss: pathophysiology and clinical perspectives.
The oncologist, 13 2
-
Matthew
Smith
(2004)
Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.
Urology, 63 4
-
S.
Alibhai,
M.
Duong-Hua,
R.
Sutradhar,
N.
Fleshner,
P.
Warde,
A.
Cheung,
L.
Paszat
(2009)
Impact of androgen deprivation therapy on cardiovascular disease and diabetes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 21
-
R.
Eastell,
J.
Adams,
R.
Coleman,
A.
Howell,
R.
Hannon,
J.
Cuzick,
J.
Mackey,
M.
Beckmann,
G.
Clack
(2008)
Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 7